Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Estrogen across the menstrual cycle for females with inflammatory bowel disease

Award Number: R01DK142904
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/21/2026
PERIOD OF PERFORMANCE END DATE: 01/31/2031

Group Awards By:

View Award Description

Estrogen across the menstrual cycle for females with inflammatory bowel disease - SUMMARY/ABSTRACT Inflammatory bowel disease (IBD) is an autoimmune condition which leads to symptoms of abdominal pain and diarrhea. In women with IBD, symptoms (e.g., abdominal pain and diarrhea) vary with their menstrual cycle phase, however, there is limited clinical data linking estrogen or progesterone fluctuations to systemic or localized gut inflammation. Our project aims to reduce this gap in knowledge by testing the relationships between estrogen levels and systemic indicators of inflammation (e.g., cytokines, CRP) as well as gastrointestinal (GI)-specific markers (i.e., fecal calprotectin, bowel wall thickness) among women with IBD. We will also describe important patient-reported outcomes including daily symptoms and life interference, quality of life. The study design accounts for the impact of two distinct phases of the menstrual cycle (mid- luteal vs. menses) and compares those with IBD to healthy controls (HCs) and those with a disorder of gut- brain interaction (DGBIs) (n=50 per group). Participants will track their menstrual cycle and will complete daily symptom reports. The specific aims are: 1) To compare systemic (i.e., cytokines, CRP) and GI-specific (i.e., fecal calprotectin) inflammatory markers and patient-reported outcomes (i.e., symptoms, quality of life) in females across IBD, HCs, and DGBI groups and between mid-luteal and menses phases; 2) To determine the relationship between estrogen and systemic and GI-specific inflammatory markers, and patient-reported outcomes during mid-luteal and menses phases across IBD, HCs, and DGBI groups; 3) (a) To evaluate bowel wall thickness between mid-luteal and menses phase and (b) to determine the relationship between estrogen levels and bowel wall thickness across IBD, HCs, and DGBI groups. Better understanding the impact of the menstrual cycle on systemic and GI-specific inflammation and patient-reported outcomes in IBD is the first foundational step needed to realize our goal improving the health of women with autoimmune conditions.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $782,361 )
2026	2026	UNIVERSITY OF WASHINGTON	4333 BROOKLYN AVE NE	SEATTLE	WA	98195	KING	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	3/20/2026	NEW	$782,361
														Subtotal = $782,361

Grand Total All Awards = $782,361

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Estrogen across the menstrual cycle for females with inflammatory bowel disease

Award Number: R01DK142904

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/21/2026

PERIOD OF PERFORMANCE END DATE: 01/31/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer